Primary Research · 2003
Acetyl-L-carnitine for the treatment of mild cognitive impairment and mild Alzheimer's disease: a meta-analysis of clinical trials
Montgomery SA, Thal LJ, Amrein R · International Clinical Psychopharmacology, 2003
Key finding
Meta-analysis of 21 double-blind RCTs found ALCAR significantly improved cognition vs placebo in mild cognitive impairment and early Alzheimer's, with effect size growing over time.
About the supplement
Acetyl-L-Carnitine (ALCAR)
Dose · mechanism · evidence grade · safety →
Read the paper
Open on PubMedhttps://pubmed.ncbi.nlm.nih.gov/12598816/
About this page
Formulate maintains a registry of clinical studies cited across its guides and evidence grades. This page links the study metadata to the content that cites it — one canonical entry per landmark study.
The full citation chain is public so readers can verify claims without hunting through individual guide pages. Browse all cited studies →
Note: Study summaries on this page are editorial interpretations of the research. Always consult the primary source before drawing clinical conclusions.